The European Bronchiectasis Registry (EMBARC) is a multidisciplinary research network advancing knowledge across the full spectrum of bronchiectasis. As of 2025, it has collected data from over 20,000 patients in more than 30 countries, forming one of the largest real-world bronchiectasis datasets globally. This infrastructure supports international research and clinical trials, with AI-based imaging increasingly enabling deeper disease phenotyping and mechanistic insights.
Through collaborative initiatives with study sponsors, we partner with EMBARC as part of the EMBARC-BRIDGE initiative, applying AI-powered lung image analysis to enable deeper insights and a more comprehensive understanding of bronchiectasis disease mechanisms. This work is instrumental in generating robust clinical evidence and high-quality scientific publications, ultimately strengthening the scientific foundation for improved patient care.
Over 600 thoracic CT scans analyzed using advanced AI-based methods, with further analyses currently in progress
Integration of quantitative imaging biomarkers into the EMBARC registry, enhancing clinical data with objective structural CT metrics
Development of cross-sectional and longitudinal datasets, enabling robust associations between imaging biomarkers, clinical outcomes, and disease progression
Thirona conducts automated AI-based analysis of thoracic CT scans using LungQ® Bronchus–Artery (BA) and LungQ® Mucus Plug (MP), providing quantitative evidence for:
These analyses continue to reveal substantial variation in structural lung changes, both within individual patients and across patient cohorts, highlighting pronounced intra- and inter-patient heterogeneity, as demonstrated in recent publications.
When integrated with patient-level registry data, these imaging biomarkers enable longitudinal assessment and contribute to deeper phenotyping and improved disease stratification within the EMBARC registry, supporting ongoing research and future discoveries.
